On Friday, Medical Properties Trust, Inc. (NYSE:MPW)’s shares declined -3.01% to $10.95.
Medical Properties Trust, Inc. (the “Company” or “MPT”) (MPW) recently declared that the formerly revealed acquisition of Capella Holdings, Inc. (“Capella”) has been accomplished. Capella Health Holdings LLC, an associate of MPT jointly owned with current Capella administration, closed the acquisition and began operating the Capella facilities on Monday, August 31.
Medical Properties Trust, Inc. operates as a real estate investment trust (REIT) in the United States. It acquires, develops, and invests in healthcare facilities; and leases healthcare facilities to healthcare operating companies and healthcare providers. The company also provides mortgage loans to healthcare operators, in addition to working capital and other term loans to its tenants/borrowers.
American Electric Power Company Inc (NYSE:AEP)’s shares dropped -1.48% to $52.54.
Greensmith, a leading provider of grid-scale energy storage software and integration solutions, declared recently that it has accomplished its $12.3 million Series C round of financing. The round was led with a $5 million dollar planned investment from American Electric Power (NYSE: AEP), one of the largest electric utilities in the United States, serving nearly 5.4 million customers in 11 states.
Securing a planned investment from a premier utility is a key component in solidifying Greensmith’s leadership position in the energy storage industry. With an industry-leading technology platform, a track record of successful deployments, and strong customer and partner relationships, Greensmith is poised to take a noteworthy share of the growing number of grid-scale storage opportunities.
American Electric Power Company, Inc., a public utility holding company, engages in the generation, transmission, and distribution of electricity for sale to retail and wholesale customers. The company generates electricity using coal and lignite, natural gas, nuclear, and hydroelectric and other energy sources. It also supplies and markets electric power at wholesale to other electric utility companies, rural electric cooperatives, municipalities, and other market participants.
At the end of Friday’s trade, AstraZeneca plc (ADR) (NYSE:AZN)‘s shares dipped -1.71% to $31.70.
Data will be stated from across AstraZeneca’s industry-leading lung cancer portfolio at the World Conference on Lung Cancer (WCLC) 2015, startning this weekend in Denver, Colorado. Presentations will feature 25 abstracts (counting 9 oral and 4 late breaker presentations) on the company’s lung cancer pipeline, designed to address the unmet needs of patients with different forms of lung cancer.
AZD9291 (osimertinib)1: Targeting resistance mechanisms in lung cancer
AZD9291 will be the focus of six oral presentations on its clinical activity in both first-line and formerly-treated patients with epidermal growth factor receptor mutation (EGFRm) T790M advanced non-small cell lung cancer (NSCLC). The data are compriseent with formerly stated efficacy and safety results of AZD9291 in these treatment settings.
Antoine Yver, Head of Oncology, Global Medicines Development at AstraZeneca said: “The data presented at WCLC illustrate the breadth of our lung cancer research across multiple disease settings and lines of therapy, as we aim to develop a comprehensive portfolio of effective and durable treatments for patients. AZD9291 is moving through clinical development with unprecedented speed, and was recently granted US Precedingity Review designation in recognition of its potential to target the mutation that drives resistance to current treatments for EGFR mutation positive advanced non-small cell lung cancer in the majority of patients.”
In addition to AZD9291, AstraZeneca will also present results from the IRESSA® (gefitinib) Clinical Access Program (ICAP), which provides data on the long-term safety and tolerability of the EGFR tyrosine kinase inhibitor in 188 US cancer patients outside the clinical trial setting. IRESSA® was approved by the US Food and Drug Administration (FDA) in July 2015, and is already accessible in 91 countries worldwide.
AstraZeneca PLC engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. Its products comprise Crestor for the treatment of dyslipidaemia and hypercholesterolemia; Seloken/Toprol-XL to control hypertension, and heart failure and angina; Onglyza for diabetes mellitus; Iressa for non-small cell lung cancer; Faslodex for breast cancer in post-menopausal women; Zoladex for prostate cancer, breast cancer, and certain benign gynaecological disorders; Pulmicort Turbuhaler/Pulmicort Flexhaler for treating asthma; Symbicort for maintenance treatment of asthma and chronic obstructive pulmonary disease; Nexium for treatment of acid-related diseases; Seroquel XR for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and generalised anxiety disorder; and Synagis for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus in paediatric patients.
Zimmer Biomet Holdings Inc (NYSE:ZBH), ended its Friday’s trading session with -1.62% loss, and closed at $100.46.
Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, declared that it will be participating in the Morgan Stanley 2015 Global Healthcare Conference at the Grand Hyatt in New York, on Thursday, September 17, 2015. Zimmer Biomet will present at 2:05 p.m. Eastern Time.
Zimmer Biomet Holdings, Inc., together with its auxiliaries, designs, develops, manufactures, and markets orthopaedic reconstructive devices, spinal and trauma devices, biologics, dental implants, and related surgical products in the Americas, Europe, and the Asia Pacific. It offers orthopaedic reconstructive devices that restore function lost due to disease or trauma in joints comprising knees, hips, shoulders, and elbows; dental reconstructive implants, which restore function and aesthetics in patients who have lost teeth due to trauma or disease; spinal devices that are utilized by orthopedic surgeons and neurosurgeons for the treatment of degenerative diseases, deformities, and trauma in various regions of the spine; and trauma devices used primarily to reattach or stabilize damaged bone and tissue to support the bodys natural healing process.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
